Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

Author： Müller Thomas

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.8, 2013-08, pp. : 1015-1024

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Istradefylline, a novel adenosine A_2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Istradefylline for the treatment of Parkinson's disease

By Park Ariane Stacy Mark

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 111-114

Informa Healthcare

Access to resources Recommend Favorite

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

By Perez-Lloret Santiago Merello Marcelo

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1097-1107

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease

By Deleu D.

Clinical Pharmacokinetics, Vol. 41, Iss. 4, 2002-01 ,pp. : 261-309

Adis International

Access to resources Recommend Favorite

Istradefylline effective adjunct therapy for Parkinson's disease

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite